CSI Market
Sign In | Register

Sanofi (SNY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SNY Annual Cash Flow →
This page allows investors to follow Sanofi's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income0.00
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets-394.24
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Non Current Provisions And Other Non Current Liabilities-
Adjustments For Sharebased Payments-
Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset-
Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates-
Cash Flows From Used In Operations Before Changes In Working Capital-
Adjustments For Decrease Increase In Inventories-
Adjustments For Increase Decrease In Trade Account Payable-
Net Change In Other Current Assets And Other Current Liabilities-
Income taxes-2,731.68
Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method324.80
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable-1,346.24
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Other Adjustments To Reconcile Profit Loss305.76
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3,890.88
Discontinued operations0.00
Net Cash flow from Operating Activities12,040.00
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets-
Proceeds From Sales Of Investments Accounted For Using Equity Method-
Net Change In Other Non Current Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Purchase Of Financial Instruments Classified As Investing Activities-766.08
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash FlowsFrom Losing Control Of Subsidiaries OrOther Businesses Classified As Investing Activities0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-2,833.60
Discontinued operations0.00
Net Cash Flow from Investing Activities-2,740.64
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-2,936.64
Long-term debt - repayments6,226.08
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7,089.60
Payments To Acquire Or Redeem Entitys Shares-
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-9,191.84
Effect of exchange rate on cash flow-52.64
Discontinued operations0.00
Free Cash Flow12,040.00
Total Cash Flow8,333.92
4 historic quarters locked

Sign in to unlock the full Sanofi cash flow history.

Sign In Create Free Account

About Sanofi Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: February 17, 2026
  • Source: sny-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-008403

Figures are derived from filed reports and may be restated. Historical data is subject to revision.